NCT02765854 · OUTCOME

Percentage of Patients With Response at Baseline and at 12 Months

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement · Source last updated 2025-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: Not reported
Time frame: At baseline and at 12 months

What was measured

Determine percentage of patients with response at 8 cycles of treatment

Groups in this outcome

Arm B (Ixazomib and Dexamethasone)

MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A. Dexamethasone: Given PO Ixazomib: Given PO

Arm C (Ixazomib, Dexamethasone, Lenalidomide)

MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21. Dexamethasone: Given PO Ixazomib: Given PO Lenalidomide: Given PO

Arm A (Ixazomib and Dexamethasone)

UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone. Dexamethasone: Given PO Ixazomib: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm B (Ixazomib and Dexamethasone)	22
Arm C (Ixazomib, Dexamethasone, Lenalidomide)	21
Arm A (Ixazomib and Dexamethasone)	27

Reported measurements

Baseline

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm B (Ixazomib and Dexamethasone)	31	Not reported	Not reported	Not reported	Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)	42	Not reported	Not reported	Not reported	Not reported
Arm A (Ixazomib and Dexamethasone)	37	Not reported	Not reported	Not reported	Not reported

Month 12

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm B (Ixazomib and Dexamethasone)	35	Not reported	Not reported	Not reported	Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)	35	Not reported	Not reported	Not reported	Not reported
Arm A (Ixazomib and Dexamethasone)	73	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
31
group Id
OG001
value
42
group Id
OG002
value
37
title
Baseline
categories
measurements
group Id
OG000
value
35
group Id
OG001
value
35
group Id
OG002
value
73
title
Month 12

denoms

counts
group Id
OG000
value
22
group Id
OG001
value
21
group Id
OG002
value
27
units
Participants

description

Determine percentage of patients with response at 8 cycles of treatment

groups

description
MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A. Dexamethasone: Given PO Ixazomib: Given PO
id
OG000
title
Arm B (Ixazomib and Dexamethasone)
description
MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21. Dexamethasone: Given PO Ixazomib: Given PO Lenalidomide: Given PO
id
OG001
title
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
description
UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone. Dexamethasone: Given PO Ixazomib: Given PO
id
OG002
title
Arm A (Ixazomib and Dexamethasone)

param Type

NUMBER

reporting Status

POSTED

time Frame

At baseline and at 12 months

title

Percentage of Patients With Response at Baseline and at 12 Months

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice